Skip to main content

    Bristol Myers Squibb (BMY) stock analysis and AI score

    Bristol Myers Squibb has a Peakwise AI stock score of 57 out of 100, a mixed profile, ranked 20 of 51 stocks as of Nov 6, 2026. The score describes price history and ratios. It is no advice.

    Mixed profile

    Ranked 20 of 51 by AI score

    End of day data as of Nov 6, 2026

    AI Score Parts. Weights and values.

    The Bristol Myers Squibb score is a weighted average of 6 parts. Each part ranks the stock from 0 to 100 against the other 50 stocks on the list, and 100 is the best rank.

    Quality and valuation use company ratios such as net margin, debt and earnings yield.

    • Momentum weight 30%57
    • Trend weight 20%44
    • Volatility weight 15%56
    • Drawdown weight 15%79
    • Quality weight 10%31
    • Valuation weight 10%81

    Price and Range. End of day Nov 6, 2026.

    $62.14

    Last close of BMY in US dollars, as of Nov 6, 2026. Not a live quote.

    1 month
    +4.3%
    6 months
    +10.6%
    1 year
    +33.7%
    52 week low$45.27Last close$62.1452 week high$68.64

    What This Score Means. Mixed profile.

    A score of 57 gives Bristol Myers Squibb a mixed profile. Mixed means the score sits between the weak and the strong bands.

    Valuation is the strongest part at 81, weighted 10%. It looks at earnings yield and free cash flow yield. Quality is the weakest at 31, weighted 10%. It looks at net margin and debt.

    As of Nov 6, 2026 the last close was $62.14. Bristol Myers Squibb sits 7 points above the middle of the list (a median of 50).

    A mixed score is no warning and no green light. Read the parts to see where it comes from.

    About Bristol Myers Squibb. Pharmaceuticals.

    Bristol Myers Squibb develops medicines for cancer, blood disorders, heart disease and immune conditions. Opdivo and Eliquis, the latter sold together with Pfizer, are among its main products. It bought Celgene in 2019, a deal that reshaped its drug lineup.

    Ticker
    BMY
    Sector
    Health Care
    Industry
    Pharmaceuticals
    Headquarters
    United States

    Score FAQ. About Bristol Myers Squibb.

    Bristol Myers Squibb (BMY) has an AI score of 57 out of 100 as of Nov 6, 2026. That is a mixed profile, and it ranks 20 of 51 stocks on the Peakwise list.

    The score is a weighted average of 6 parts: Momentum 30% (57), Trend 20% (44), Volatility 15% (56), Drawdown 15% (79), Quality 10% (31), Valuation 10% (81). Each part ranks Bristol Myers Squibb against the other 50 stocks on the list from 0 to 100, using end of day prices.

    Once per trading day, after the market has closed. This page shows the score and price as of Nov 6, 2026. It is not a live quote.

    No. The score describes price history and a few ratios compared with the rest of the list. It does not know your goals, it makes no forecast and it is not investment advice.

    End of day price data from a market data provider, plus company ratios where they are available. Peakwise calculates the parts and the score itself. Prices are in US dollars and dated Nov 6, 2026. The company profile on this page is written by Peakwise.

    Research, not advice

    Peakwise is a research tool. The AI score of Bristol Myers Squibb describes end of day price history and a few ratios compared with other large US stocks. It is not investment advice, a forecast or a recommendation to buy or sell. Read how it works on the AI stock score methodology page, or use the AI stock analysis tool for risks and a fair value range.

    Go deeper. Past the score.

    The score is the short version. The AI stock analysis of Bristol Myers Squibb adds financials, a fair value range, analyst views and risks.

    7-day free trial. Basic EUR 19.99, Pro EUR 49.99 per month. Research tool, not investment advice.